USANA Health Sciences, Inc. (NYSE:USNA) Shares Sold by BNP Paribas Financial Markets

BNP Paribas Financial Markets trimmed its stake in shares of USANA Health Sciences, Inc. (NYSE:USNA) by 14.4% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 19,416 shares of the company’s stock after selling 3,279 shares during the quarter. BNP Paribas Financial Markets owned approximately 0.10% of USANA Health Sciences worth $697,000 at the end of the most recent quarter.

Several other hedge funds also recently added to or reduced their stakes in the stock. Dimensional Fund Advisors LP raised its stake in shares of USANA Health Sciences by 7.7% in the 4th quarter. Dimensional Fund Advisors LP now owns 773,228 shares of the company’s stock valued at $27,751,000 after purchasing an additional 55,059 shares in the last quarter. Pacer Advisors Inc. increased its holdings in USANA Health Sciences by 8.8% in the fourth quarter. Pacer Advisors Inc. now owns 592,001 shares of the company’s stock valued at $21,247,000 after buying an additional 47,745 shares during the last quarter. Pzena Investment Management LLC raised its stake in USANA Health Sciences by 3.6% during the fourth quarter. Pzena Investment Management LLC now owns 1,087,076 shares of the company’s stock valued at $39,015,000 after buying an additional 37,466 shares in the last quarter. Jane Street Group LLC raised its stake in USANA Health Sciences by 330.0% during the fourth quarter. Jane Street Group LLC now owns 39,979 shares of the company’s stock valued at $1,435,000 after buying an additional 30,681 shares in the last quarter. Finally, Norges Bank bought a new position in USANA Health Sciences during the 4th quarter worth approximately $953,000. 54.25% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently weighed in on the company. Sidoti downgraded USANA Health Sciences from a “strong-buy” rating to a “hold” rating in a report on Tuesday, February 18th. Wall Street Zen raised shares of USANA Health Sciences from a “hold” rating to a “buy” rating in a report on Thursday. Finally, DA Davidson dropped their target price on shares of USANA Health Sciences from $38.00 to $36.00 and set a “neutral” rating on the stock in a report on Thursday, February 27th.

USANA Health Sciences Trading Up 1.0%

Shares of USANA Health Sciences stock opened at $30.07 on Friday. The stock has a market capitalization of $559.90 million, a price-to-earnings ratio of 10.62, a PEG ratio of 0.93 and a beta of 0.60. USANA Health Sciences, Inc. has a twelve month low of $23.10 and a twelve month high of $49.16. The business’s 50 day simple moving average is $27.08 and its 200-day simple moving average is $32.26.

USANA Health Sciences (NYSE:USNA) last issued its earnings results on Tuesday, April 22nd. The company reported $0.73 earnings per share for the quarter, topping the consensus estimate of $0.70 by $0.03. The firm had revenue of $249.54 million for the quarter, compared to analyst estimates of $243.08 million. USANA Health Sciences had a return on equity of 10.64% and a net margin of 6.30%. During the same period last year, the company earned $0.86 earnings per share. Sell-side analysts predict that USANA Health Sciences, Inc. will post 2.45 earnings per share for the current year.

Insiders Place Their Bets

In related news, insider David Mulham Mulham sold 3,234 shares of the stock in a transaction dated Monday, March 10th. The shares were sold at an average price of $32.98, for a total value of $106,657.32. Following the completion of the transaction, the insider now owns 12,775 shares in the company, valued at $421,319.50. This represents a 20.20% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Also, CEO Jim Brown sold 5,000 shares of the business’s stock in a transaction dated Monday, March 3rd. The stock was sold at an average price of $29.47, for a total transaction of $147,350.00. Following the sale, the chief executive officer now owns 15,716 shares in the company, valued at $463,150.52. This trade represents a 24.14% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders sold 21,142 shares of company stock worth $655,050. Insiders own 0.63% of the company’s stock.

USANA Health Sciences Profile

USANA Health Sciences, Inc develops, manufactures, and sells science-based nutritional, personal care, and skincare products in the Asia Pacific, the Americas, and Europe. The company offers USANA nutritional products that comprise essentials/CellSentials, such as vitamin and mineral supplements that provide a foundation of total body nutrition for various age groups; optimizers consisting of targeted supplements that are designed to meet cardiovascular, skeletal/structural, and digestive health needs; and food that include meal replacement shakes, snack bars, and other related products.